Suxibuzone

Suxibuzone (CAS No.: 27470-51-5) is a synthetic small molecule classified within the non steroidal anti inflammatory research class and is broadly characterized as a prodrug related to phenylbutazone, making it relevant for pharmacology studies focused on inflammatory and pain associated biology in preclinical systems; in biomedical research and drug discovery workflows, it is commonly used as a reference compound to investigate cyclooxygenase associated prostaglandin signaling and downstream inflammatory mediator regulation, with mechanistic interpretation generally based on biotransformation to an active phenylbutazone like species that modulates arachidonic acid pathway output and related immune and stromal cell responses, while direct target level assignment to the parent molecule remains context dependent and may vary with metabolic capacity of the test system; because publicly reported assay specific potency metrics for the parent compound are limited across standardized in vitro platforms, activity is typically discussed qualitatively or inferred from class behavior in the micromolar domain rather than assigned as a single definitive IC50 or EC50 value, and experimental use commonly includes cell based inflammation models, comparative profiling against other non steroidal anti inflammatory agents, and animal based translational pharmacology paradigms where dose selection, exposure windows, and endpoint panels are determined by the specific study design and research objectives.